Merck 0.94B Volume Dips 39.97% to Rank 116th as Alzheimer’s Pipeline Shifts Gain Momentum

Merck (MRK) rose 1.50% on August 1, 2025, with a trading volume of $0.94 billion, a 39.97% decline from the prior day, ranking 116th in market activity. The stock’s performance reflects renewed focus on its Alzheimer’s drug pipeline amid strategic cost-cutting measures. Merck is advancing two mid-stage candidates—MK-2214, a tau-targeting antibody, and MK-1167, an alpha-7 neurotransmitter modulator—aimed at addressing earlier-stage disease progression. The company’s shift toward precision medicine and biomarker-driven therapies underscores its bid to reclaim leadership in a competitive Alzheimer’s landscape, previously hindered by failed BACE inhibitor programs.

Merck’s strategy includes streamlining operations, including layoffs, to offset near-term challenges from Keytruda’s patent expiration. The firm is prioritizing neuroscience research, leveraging genetic insights and biomarker tracking to refine trial design. Dr. Mike Egan, head of neuroscience clinical development, emphasized the importance of identifying optimal therapeutic windows and patient cohorts to avoid past trial pitfalls. The approach aligns with industry trends toward earlier intervention and disease-modifying therapies, positioning Merck to compete with Lilly’s Kisunla and Biogen/Eisai’s Leqembi.

The backtest results indicate that a strategy of purchasing the top 500 stocks by daily trading volume and holding for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark’s 29.18% by 137.53%. This highlights the efficacy of liquidity-focused strategies in capturing short-term market movements, particularly in volatile sectors like biotech and pharma.